Skip to main content
Erschienen in: Die Nephrologie 5/2019

21.08.2019 | Harnwegsinfektionen | CME

Prophylaktische Behandlung von Patienten mit medikamentöser Immunsuppression

verfasst von: Prof. Dr. J. Lutz, A. Rieke

Erschienen in: Die Nephrologie | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit einer medikamentösen Immunsuppression im Rahmen von Autoimmunerkrankungen, Organtransplantationen oder Komplementerkrankungen haben ein erhöhtes Risiko für Infektionserkrankungen. Dabei nimmt die Häufigkeit von Infektionserkrankungen mit der Ausprägung der Immunsuppression zu. Zudem treten bestimmte Infektionserkrankungen besonders im Zusammenhang mit einzelnen Immunsuppressiva wie z. B. Komplementhemmern auf. Zur Prophylaxe von Infektionserkrankungen bei immunsuppressiver Therapie werden neben allgemeinen Maßnahmen vor allem Antibiotika und Impfungen eingesetzt. Impfungen müssen vor Beginn einer immunsuppressiven Therapie geplant werden, da z. B. Lebendimpfungen nach der Transplantation nicht mehr erfolgen können. Insgesamt lässt sich durch eine entsprechende Prophylaxe die Anzahl der Infektionen im Rahmen einer immunsuppressiven Therapie deutlich reduzieren.
Literatur
1.
Zurück zum Zitat Fardet L, Petersen I, Nazareth I (2016) Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med 13:e1002024CrossRefPubMedPubMedCentral Fardet L, Petersen I, Nazareth I (2016) Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med 13:e1002024CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Youssef J, Novosad SA, Winthrop KL (2016) Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 42:157–176CrossRefPubMed Youssef J, Novosad SA, Winthrop KL (2016) Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 42:157–176CrossRefPubMed
3.
Zurück zum Zitat Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 318:432–442CrossRefPubMedPubMedCentral Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 318:432–442CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Rauen T, Fitzner C, Eitner F et al (2018) Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol 29:317–325CrossRefPubMed Rauen T, Fitzner C, Eitner F et al (2018) Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol 29:317–325CrossRefPubMed
5.
Zurück zum Zitat Martin SI, Fishman JA, Practice ASTIDCO (2013) Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 13(Suppl 4):272–279CrossRefPubMed Martin SI, Fishman JA, Practice ASTIDCO (2013) Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 13(Suppl 4):272–279CrossRefPubMed
6.
Zurück zum Zitat Husain S, Singh N (2002) The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 35:53–61CrossRefPubMed Husain S, Singh N (2002) The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 35:53–61CrossRefPubMed
7.
Zurück zum Zitat Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228CrossRefPubMed Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228CrossRefPubMed
8.
Zurück zum Zitat Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112CrossRefPubMedPubMedCentral Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Henderson LK, Masson P, Craig JC et al (2013) Induction and maintenance treatment of proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis 61:74–87CrossRefPubMed Henderson LK, Masson P, Craig JC et al (2013) Induction and maintenance treatment of proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis 61:74–87CrossRefPubMed
10.
Zurück zum Zitat Singh JA, Hossain A, Kotb A et al (2016) Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: A systematic review and network meta-analysis. BMC Med 14:137CrossRefPubMedPubMedCentral Singh JA, Hossain A, Kotb A et al (2016) Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: A systematic review and network meta-analysis. BMC Med 14:137CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Bowman LJ, Brueckner AJ, Doligalski CT (2018) The role of mTOR inhibitors in the management of viral infections: A review of current literature. Transplantation 102:S50–S59CrossRefPubMed Bowman LJ, Brueckner AJ, Doligalski CT (2018) The role of mTOR inhibitors in the management of viral infections: A review of current literature. Transplantation 102:S50–S59CrossRefPubMed
12.
Zurück zum Zitat Mallat SG, Tanios BY, Itani HS et al (2017) CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: A systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 12:1321–1336CrossRefPubMedPubMedCentral Mallat SG, Tanios BY, Itani HS et al (2017) CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: A systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 12:1321–1336CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220CrossRefPubMed Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220CrossRefPubMed
14.
Zurück zum Zitat Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232CrossRefPubMedPubMedCentral Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Tony HP, Burmester G, Schulze-Koops H et al (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID). Arthritis Res Ther 13:R75CrossRefPubMedPubMedCentral Tony HP, Burmester G, Schulze-Koops H et al (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID). Arthritis Res Ther 13:R75CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834–4840CrossRefPubMedPubMedCentral Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834–4840CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Iriart X, Challan Belval T, Fillaux J et al (2015) Risk factors of pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant 15:190–199CrossRefPubMed Iriart X, Challan Belval T, Fillaux J et al (2015) Risk factors of pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant 15:190–199CrossRefPubMed
19.
Zurück zum Zitat Green H, Paul M, Vidal L et al (2007) Prophylaxis for Pneumocystis Pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10:CD5590 Green H, Paul M, Vidal L et al (2007) Prophylaxis for Pneumocystis Pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10:CD5590
20.
Zurück zum Zitat Martin-Gandul C, Mueller NJ, Pascual M et al (2015) The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant 15:3024–3040CrossRefPubMed Martin-Gandul C, Mueller NJ, Pascual M et al (2015) The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant 15:3024–3040CrossRefPubMed
21.
Zurück zum Zitat Kalil AC, Freifeld AG, Lyden ER et al (2009) Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS ONE 4:e5512CrossRefPubMedPubMedCentral Kalil AC, Freifeld AG, Lyden ER et al (2009) Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS ONE 4:e5512CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Owers DS, Webster AC, Strippoli GF et al (2013) Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2:CD5133 Owers DS, Webster AC, Strippoli GF et al (2013) Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2:CD5133
23.
Zurück zum Zitat Manuel O, Kralidis G, Mueller NJ et al (2013) Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 13:2402–2410CrossRefPubMed Manuel O, Kralidis G, Mueller NJ et al (2013) Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 13:2402–2410CrossRefPubMed
24.
Zurück zum Zitat Adamu B, Abdu A, Abba AA et al (2014) Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. Cochrane Database Syst Rev 3:CD8597 Adamu B, Abdu A, Abba AA et al (2014) Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. Cochrane Database Syst Rev 3:CD8597
25.
Zurück zum Zitat Hollyer I, Ison MG (2018) The challenge of urinary tract infections in renal transplant recipients. Transpl Infect Dis 20:e12828CrossRefPubMed Hollyer I, Ison MG (2018) The challenge of urinary tract infections in renal transplant recipients. Transpl Infect Dis 20:e12828CrossRefPubMed
26.
Zurück zum Zitat Green H, Rahamimov R, Gafter U et al (2011) Antibiotic prophylaxis for urinary tract infections in renal transplant recipients: A systematic review and meta-analysis. Transpl Infect Dis 13:441–447CrossRefPubMed Green H, Rahamimov R, Gafter U et al (2011) Antibiotic prophylaxis for urinary tract infections in renal transplant recipients: A systematic review and meta-analysis. Transpl Infect Dis 13:441–447CrossRefPubMed
27.
Zurück zum Zitat Rafat C, Vimont S, Ancel PY et al (2011) Ofloxacin: New applications for the prevention of urinary tract infections in renal graft recipients. Transpl Infect Dis 13:344–352CrossRefPubMed Rafat C, Vimont S, Ancel PY et al (2011) Ofloxacin: New applications for the prevention of urinary tract infections in renal graft recipients. Transpl Infect Dis 13:344–352CrossRefPubMed
28.
Zurück zum Zitat Liu S, Luo G, Sun B et al (2017) Early removal of double-J stents decreases urinary tract infections in living donor renal transplantation: A prospective, randomized clinical trial. Transplant Proc 49:297–302CrossRefPubMed Liu S, Luo G, Sun B et al (2017) Early removal of double-J stents decreases urinary tract infections in living donor renal transplantation: A prospective, randomized clinical trial. Transplant Proc 49:297–302CrossRefPubMed
29.
Zurück zum Zitat Hurst FP, Lee JJ, Jindal RM et al (2011) Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol 6:1192–1197CrossRefPubMedPubMedCentral Hurst FP, Lee JJ, Jindal RM et al (2011) Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol 6:1192–1197CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Perez-Romero P, Aydillo TA, Perez-Ordonez A et al (2012) Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease. Clin Microbiol Infect 18:E533–E540CrossRefPubMed Perez-Romero P, Aydillo TA, Perez-Ordonez A et al (2012) Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease. Clin Microbiol Infect 18:E533–E540CrossRefPubMed
32.
Zurück zum Zitat Vink P, Ramon Torrell JM, Sanchez Fructuoso A et al (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically Immunosuppressed adults following renal transplant: A phase III, randomized clinical trial. Clin Infect Dis. https://doi.org/10.1093/cid/ciz177 CrossRefPubMed Vink P, Ramon Torrell JM, Sanchez Fructuoso A et al (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically Immunosuppressed adults following renal transplant: A phase III, randomized clinical trial. Clin Infect Dis. https://​doi.​org/​10.​1093/​cid/​ciz177 CrossRefPubMed
Metadaten
Titel
Prophylaktische Behandlung von Patienten mit medikamentöser Immunsuppression
verfasst von
Prof. Dr. J. Lutz
A. Rieke
Publikationsdatum
21.08.2019
Verlag
Springer Medizin
Erschienen in
Die Nephrologie / Ausgabe 5/2019
Print ISSN: 2731-7463
Elektronische ISSN: 2731-7471
DOI
https://doi.org/10.1007/s11560-019-0365-4

Weitere Artikel der Ausgabe 5/2019

Die Nephrologie 5/2019 Zur Ausgabe